StockData
Exagen Inc. logo

Exagen Inc. (XGN) stock

XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)

Close on Nov 17, 2026Market cap $91.09MP/E –Yield –

Exagen cash

Cash and short-term investments held at the end of each period.

Exagen's cash was $24.59M at Jun 30, 2026. For fiscal 2025 it was $32.22M, up 44.9% from the year before. The highest annual figure on record is $99.54M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.22M+44.9%
FY2024Dec 31, 2024$22.24M-39.4%
FY2023Dec 31, 2023$36.69M-41.4%
FY2022Dec 31, 2022$62.59M-37.1%
FY2021Dec 31, 2021$99.54M+73.0%
FY2020Dec 31, 2020$57.55M-20.3%
FY2019Dec 31, 2019$72.18M+444.2%
FY2018Dec 31, 2018$13.26M+17.0%
FY2017Dec 31, 2017$11.34M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$24.59M-18.7%
Q1 FY2026Mar 31, 2026$21.51M+88.8%
Q4 FY2025Dec 31, 2025$32.22M+44.9%
Q3 FY2025Sep 30, 2025$35.65M+60.3%
Q2 FY2025Jun 30, 2025$30.23M+22.5%
Q1 FY2025Mar 31, 2025$11.39M-58.5%
Q4 FY2024Dec 31, 2024$22.24M-39.4%
Q3 FY2024Sep 30, 2024$22.24M-22.4%
Q2 FY2024Jun 30, 2024$24.68M-22.1%
Q1 FY2024Mar 31, 2024$27.47M-47.6%
Q4 FY2023Dec 31, 2023$36.69M-41.4%
Q3 FY2023Sep 30, 2023$28.65M-58.4%
Q2 FY2023Jun 30, 2023$31.67M-58.6%
Q1 FY2023Mar 31, 2023$52.38M-41.6%
Q4 FY2022Dec 31, 2022$62.59M-37.1%
Q3 FY2022Sep 30, 2022$68.90M-35.5%
Q2 FY2022Jun 30, 2022$76.49M-32.1%
Q1 FY2022Mar 31, 2022$89.75M-24.0%
Q4 FY2021Dec 31, 2021$99.54M+73.0%
Q3 FY2021Sep 30, 2021$106.77M+73.5%
Q2 FY2021Jun 30, 2021$112.68M+76.6%
Q1 FY2021Mar 31, 2021$118.15M+71.9%
Q4 FY2020Dec 31, 2020$57.55M-20.3%
Q3 FY2020Sep 30, 2020$61.53M-21.0%
Q2 FY2020Jun 30, 2020$63.80M+290.5%
Q1 FY2020Mar 31, 2020$68.75M+376.5%
Q4 FY2019Dec 31, 2019$72.18M+444.2%
Q3 FY2019Sep 30, 2019$77.93M+1322.0%
Q2 FY2019Jun 30, 2019$16.34M+44.1%
Q1 FY2019Mar 31, 2019$14.43M–
Q4 FY2018Dec 31, 2018$13.26M–
Q3 FY2018Sep 30, 2018$5.48M–
Q4 FY2017Dec 31, 2017$11.34M–

More Exagen figures

See a number that looks wrong?